TITLE:
The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

CONDITION:
HIV Infections

INTERVENTION:
Interferon gamma-1b

SUMMARY:

      To determine safety and tolerance of administering aerosolized recombinant interferon gamma
      (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages
      by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of
      IFN-gamma can activate alveolar macrophages in AIDS patients.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Diagnosis of AIDS with one or more opportunistic infections.

          -  Kaposi's sarcoma with prior history of opportunistic infection.

          -  Stable dose of zidovudine (AZT) therapy.

          -  Preserved pulmonary, renal and hepatic function.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Presence of active infection.

          -  Active opportunistic infections.

          -  Cardiac disease.

          -  Central nervous system disorders.

          -  History of seizures.

          -  Irreversible airway disease.

        Patients with the following are excluded:

          -  Co-existing conditions and symptoms listed in Patient Exclusion Co-existing
             Conditions.

        Prior Medication:

        Excluded within 4 weeks of study entry:

          -  Immunosuppressive therapy.

          -  Cytotoxic therapy.

          -  Excluded:

          -  Interferon gamma therapy.
      
